Renal denervation for hypertension management: past, current evidence, and future directions
American Journal of Hypertension · 2026
DOI: 10.1093/ajh/hpag112 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hypertension, 2026. Verfasst von Shahzad Hassan und 5 weiteren Autor:innen. Beteiligte Einrichtung: American Heart Association Certified Hypertension Center, Division of Cardiovascular Medicine, University of Miami Healthy System, Miami, FL, United …. Hauptthemen laut MEDLINE: Hypertension, Sympathectomy, Kidney, Blood Pressure. Die Arbeit nennt 124 Literaturangaben.
Abstract (Originalsprache)
Hypertension remains the most prevalent modifiable cardiovascular risk factor worldwide, and continues to account for substantial morbidity, mortality, and health care burden despite established pharmacologic and lifestyle-based therapies. Poor long-term adherence, therapeutic inertia, polypharmacy, and persistent implementation gaps have generated interest in device-based therapies that provide durable BP reduction, independent of daily medication use. Renal denervation (RDN) has emerged as the most extensively studied catheter-based intervention targeting the sympathetic pathways that contribute to BP regulation. This review summarizes the physiological basis for RDN, including the role of efferent and afferent renal sympathetic pathways in the development and maintenance of hypertension. We review the evolution of RDN technology from first-generation radiofrequency (RF) systems to multielectrode RF, ultrasound-based, and alcohol-mediated platforms, with attention to procedural refinements and lesion patterns over time. We then examine the clinical evidence across major trials, from early open-label studies to modern sham-controlled programs, which now consistently demonstrate modest but clinically meaningful reductions in ABP and OBP with an acceptable safety profile in selected patients. Beyond BP lowering, RDN may have broader biologic effects on cardiac remodeling, neurohormonal activation, inflammation, arrhythmias, metabolic dysfunction, and cardiorenal pathways, although these data remain preliminary, without any evidence from outcome studies. Important knowledge gaps persist, particularly the absence of cardiovascular outcomes trials, variability in treatment response, and the need for improved phenotyping to identify likely responders. As technology, patient selection, and mechanistic understanding continue to advance, RDN may become an increasingly important adjunct in the management of uncontrolled hypertension.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- American Heart Association Certified Hypertension Center, Division of Cardiovascular Medicine, University of Miami Healthy System, Miami, FL, United States.
- Miller School of Medicine, University of Miami, Miami, FL, United States.
- College of Arts and Sciences, University of Miami, Miami, FL, United States.
Zitieren
APA
Hassan, S., Rendon, I. H., Spilias, N., Bredel, L., Chatzizisis, Y., & Delgado-Lelievre, M. (2026). Renal denervation for hypertension management: past, current evidence, and future directions. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpag112
Vancouver
Hassan S, Rendon IH, Spilias N, Bredel L, Chatzizisis Y, Delgado-Lelievre M. Renal denervation for hypertension management: past, current evidence, and future directions. American Journal of Hypertension. 2026. doi:10.1093/ajh/hpag112
BibTeX
@article{Hassan2026,
author = {Hassan, Shahzad and Rendon, Iliana Hurtado and Spilias, Nikolaos and Bredel, Laura and Chatzizisis, Yiannis and Delgado-Lelievre, Maria},
title = {Renal denervation for hypertension management: past, current evidence, and future directions},
journal = {American Journal of Hypertension},
year = {2026},
doi = {10.1093/ajh/hpag112}
}
EUVIMED